ClinicalTrials.gg
CompletedNCT05568797Updated Sep 24, 2024Results posted

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

A Phase 3 interventional study of RSVPreF3 OA vaccine and FLU vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 37 sites in 5 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,045
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
7th of 17
1,045 · median 976
Started
2022
with 2 others
Phase 3
15 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 7th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 3, and was the 6th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU aQIV) vaccine, in adults aged 65 years of age (YOA).

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Adjuvanted quadrivalent influenza vaccine
  • Immunogenicity
  • Safety
  • Reactogenicity
  • Adults aged 65 years and above
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the electronic diary cards [eDiaries], return for follow-up visits, ability to access and utilize a phone or other electronic communications).
  • A male or female ≥ 65 YOA at the time of the first study intervention administration.
  • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
  • Written or witnessed obtained from the participant prior to performance of any study-specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of first study intervention administration. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the study interventions, in particular any history of severe allergic reaction to egg protein or to a previous influenza vaccine.
  • Hypersensitivity to latex.
  • Guillain-Barré syndrome that occurred within 6 weeks of receipt of prior influenza vaccine.
  • Serious or unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent or uncontrolled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine, or medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions, or planned use during the study period.
  • Administration of an influenza vaccine during the 6 months preceding the study FLU vaccine administration.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration. In the case of COVID-19 vaccines, this time window can be decreased to 14 days before and after each study intervention administration provided this COVID-19 vaccine use is in line with local governmental recommendations.
  • Previous vaccination with an RSV vaccine.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the administration of first dose of study interventions or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first study intervention dose or planned administration during the study period. For , this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device).

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study conduct that prohibits participation until study end.
  • Participation of any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,045 participants (actual)

Study arms

  • Experimental
    Co-Ad Group

    Participants received one dose of FLU-aQIV vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.

    Biological: RSVPreF3 OA vaccine · Biological: FLU vaccine

  • Active comparator
    Control Group

    Participants received one dose of FLU-aQIV vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until end of study.

    Biological: RSVPreF3 OA vaccine · Biological: FLU vaccine

Interventions

  • One dose of RSVPreF3 OA vaccine administered intramuscularly.

  • BiologicalFLU vaccine

    One dose of FLU vaccine administered intramuscularly.

    Also known as: Fluad Tetra, FLUAD QUADRIVALENT, Fluad Quad

06

What researchers measure

Primary outcomes

  1. Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose

    HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains.

    Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)

  2. RSV-A Neutralizing Antibody Titers Expressed as GMTs

    RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dilution 60 (ED60).

    Time frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)

  3. RSV-B Neutralizing Antibody Titers Expressed as GMTs

    RSV B neutralizing antibodies are given as GMTs and expressed as Estimated Dilution 60 (ED60).

    Time frame: At 1 month after the RSVPreF3 OA dose (Day 31 for the CoAd Group and Day 61 for the Control Group)

Secondary outcomes

  1. HI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains

    SCR for HI antibody is defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

    Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)

  2. RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)

    MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)

  3. RSV-B Neutralization Antibody Titers Expressed as MGI

    MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)

  4. Titers for HI Antibodies Against 4 FLU Vaccine Strains

    HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains. HI antibodies were expressed as GMT, in titers.

    Time frame: At Day 1 (Baseline) and Day 31

  5. HI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains

    SPR for HI antibody was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

    Time frame: At Day 1 (Baseline) and Day 31

  6. HI Antibody Titers for 4 FLU Vaccine Strains Expressed as MGI

    MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

    Time frame: At 1 month after the FLU dose (Day 31 for both groups) compared to pre-vaccination (Day 1 for both groups)

  7. Percentage of Participants Reporting Each Solicited Administration Site Event After Each Vaccine Dose Administration

    The solicited administration site events after vaccination include erythema, pain and swelling.

    Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for CoAd Group and at Day 1 and Day 31 for Control group)

  8. Percentage of Participants Reporting Each Solicited Systemic Event After Each Dose Administration

    The solicited systemic events after vaccination include fever, headache, fatigue, myalgia and arthralgia.

    Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 and Day 31 for C-oAd Group and at Day 1 and Day 31 for Control group)

  9. Percentage of Participants Reporting Unsolicited Adverse Events (AEs)

    An unsolicited AEs is an AE that is not included in a list of solicited events using a Participant Electronic Diary. Unsolicited events must be spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).

    Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine administration

  10. Percentage of Participants Reporting at Least One Serious Adverse Event (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: From Day 1 until 6 months after last vaccination (Month 6 for the Co-Ad Group, Month 7 for the Control group)

  11. Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMDs)

    pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e., pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.

    Time frame: From Day 1 until 6 months after last vaccination (Month 6 for the Co-Ad Group, Month 7 for the Control group)

07

Results

Posted Mar 15, 2024

Participant flow

All 1045 enrolled participants were randomized to Co-Ad and Control Groups and received at least 1 dose of study intervention and were included in the exposed set.

Participant flow — Overall Study
MilestoneCo-Ad GroupControl Group
Started523522
Completed518499
Not completed523
Withdrew: Adverse event08
Withdrew: Lost to follow-up23
Withdrew: Withdrawal by subject110
Withdrew: Other22

Outcome measures

PrimaryTiters for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose

HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains.

Time frame:
At 1 month after the FLU vaccine dose (Day 31 for both groups)
Reported as:
Geometric mean · Titers
Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose
TitersCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N243.8 (38.9 to 49.4)57.7 (51.0 to 65.3)
Flu A/Victoria/2570/2019 H1N1143.0 (128.6 to 159.0)148.5 (133.2 to 165.6)
Flu B/Austria/1359417/2021 Victoria613.9 (575.1 to 655.2)597.5 (558.7 to 639.1)
Flu B/Phuket/3073/2013 Yamagata406.2 (380.0 to 434.2)421.0 (393.0 to 451.0)
Statistical analysis
  • Co-Ad Group vs Control Group · Gmt ratio: 1.32 · 0.95% CI 1.13 to 1.53The comparison was done using adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group and the age category as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-Ad Group vs Control Group · Gmt ratio: 1.04 · 0.95% CI 0.91 to 1.18The comparison was done using adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group and the age category as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-Ad Group vs Control Group · Gmt ratio: 0.97 · 0.95% CI 0.90 to 1.06The comparison was done using adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group and the age category as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-Ad Group vs Control Group · Gmt ratio: 1.04 · 0.95% CI 0.95 to 1.13The comparison was done using adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group and the age category as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryRSV-A Neutralizing Antibody Titers Expressed as GMTs

RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dilution 60 (ED60).

Time frame:
At 1 month after the RSVPreF3 OA dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
Reported as:
Geometric mean · Titers
RSV-A Neutralizing Antibody Titers Expressed as GMTs
TitersCo-Ad GroupControl Group
RSV-A Neutralizing Antibody Titers Expressed as GMTs6673.4 (6057.2 to 7352.4)6591.8 (5917.8 to 7342.6)
Statistical analysis
  • Co-Ad Group vs Control Group · Gmt ratio: 0.99 · 0.95% CI 0.87 to 1.12The comparison is done using adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group and the age category as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryRSV-B Neutralizing Antibody Titers Expressed as GMTs

RSV B neutralizing antibodies are given as GMTs and expressed as Estimated Dilution 60 (ED60).

Time frame:
At 1 month after the RSVPreF3 OA dose (Day 31 for the CoAd Group and Day 61 for the Control Group)
Reported as:
Geometric mean · Titers
RSV-B Neutralizing Antibody Titers Expressed as GMTs
TitersCo-Ad GroupControl Group
RSV-B Neutralizing Antibody Titers Expressed as GMTs7880.1 (7195.4 to 8629.8)9134.1 (8255.9 to 10105.7)
Statistical analysis
  • Co-Ad Group vs Control Group · Gmt ratio: 1.16 · 0.95% CI 1.03 to 1.30The comparison is done using adjusted group ratio of GMT (ANCOVA model applied to the logarithm- transformed titers). The ANCOVA model included the treatment group, the age category as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryHI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains

SCR for HI antibody is defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

Time frame:
At 1 month after the FLU vaccine dose (Day 31 for both groups)
Reported as:
Number · Percentage of participants
HI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains
Percentage of participantsCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N251.7 (46.9 to 56.6)62.0 (57.0 to 66.8)
Flu A/Victoria/2570/2019 H1N144.0 (39.2 to 48.9)45.7 (40.7 to 50.8)
Flu B/Austria/1359417/2021 Victoria17.2 (13.8 to 21.2)17.5 (13.9 to 21.6)
Flu B/Phuket/3073/2013 Yamagata18.5 (14.9 to 22.5)19.3 (15.5 to 23.5)
Statistical analysis
  • Co-Ad Group vs Control Group · Difference of percentage: 10.25 · 0.95% CI 3.50 to 16.90
  • Co-Ad Group vs Control Group · Difference of percentage: 1.66 · 0.95% CI -5.16 to 8.47
  • Co-Ad Group vs Control Group · Difference of percentage: 0.25 · 0.95% CI -4.92 to 5.46
  • Co-Ad Group vs Control Group · Difference of percentage: 0.79 · 0.95% CI -4.54 to 6.17
SecondaryRSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)

MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
Reported as:
Geometric mean · Ratio
RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)
RatioCo-Ad GroupControl Group
RSV-A Neutralization Antibody Titers Expressed as Mean Geometric Increase (MGI)8.50 (7.79 to 9.27)7.58 (6.82 to 8.42)
SecondaryRSV-B Neutralization Antibody Titers Expressed as MGI

MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
Reported as:
Geometric mean · Ratio
RSV-B Neutralization Antibody Titers Expressed as MGI
RatioCo-Ad GroupControl Group
RSV-B Neutralization Antibody Titers Expressed as MGI7.11 (6.55 to 7.72)7.46 (6.74 to 8.25)
SecondaryTiters for HI Antibodies Against 4 FLU Vaccine Strains

HI antibodies assessed were antibodies against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata flu strains. HI antibodies were expressed as GMT, in titers.

Time frame:
At Day 1 (Baseline) and Day 31
Reported as:
Geometric mean · Titers
Titers for HI Antibodies Against 4 FLU Vaccine Strains
TitersCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N2, Day 19.1 (8.4 to 9.8)8.7 (8.1 to 9.4)
Flu A/Darwin/6/2021 H3N2 , Day 3145.3 (40.6 to 50.5)58.3 (51.6 to 65.8)
Flu A/Victoria/2570/2019 H1N1, Day 140.0 (35.4 to 45.1)43.2 (38.4 to 48.5)
Flu A/Victoria/2570/2019 H1N1, Day 31151.0 (136.4 to 167.2)163.8 (147.5 to 181.9)
Flu B/Austria/1359417/2021 Victoria, Day 1323.6 (300.4 to 348.5)327.2 (303.6 to 352.7)
Flu B/Austria/1359417/2021 Victoria, Day 31614.9 (575.5 to 657.0)608.1 (566.8 to 652.5)
Flu B/Phuket/3073/2013 Yamagata, Day 1213.1 (198.5 to 228.7)193.2 (179.9 to 207.5)
Flu B/Phuket/3073/2013 Yamagata, Day 31423.0 (394.6 to 453.5)417.5 (387.9 to 449.4)
SecondaryHI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains

SPR for HI antibody was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

Time frame:
At Day 1 (Baseline) and Day 31
Reported as:
Number · Percentage of participants
HI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains
Percentage of participantsCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N2, Day 110.4 (7.8 to 13.6)10.7 (8.0 to 13.9)
Flu A/Darwin/6/2021 H3N2, Day 3163.6 (58.9 to 68.1)71.0 (66.3 to 75.4)
Flu A/Victoria/2570/2019 H1N1, Day 160.0 (55.4 to 64.5)64.3 (59.7 to 68.8)
Flu A/Victoria/2570/2019 H1N1, Day 3192.0 (89.1 to 94.4)95.2 (92.7 to 97.1)
Flu B/Austria/1359417/2021 Victoria, Day 199.6 (98.5 to 99.9)100 (99.2 to 100)
Flu B/Austria/1359417/2021 Victoria, Day 31100 (99.2 to 100)100 (99.1 to 100)
Flu B/Phuket/3073/2013 Yamagata, Day 199.8 (98.8 to 100.0)98.9 (97.4 to 99.6)
Flu B/Phuket/3073/2013 Yamagata, Day 31100 (99.2 to 100)100 (99.1 to 100)
SecondaryHI Antibody Titers for 4 FLU Vaccine Strains Expressed as MGI

MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.

Time frame:
At 1 month after the FLU dose (Day 31 for both groups) compared to pre-vaccination (Day 1 for both groups)
Reported as:
Geometric mean · Ratio
HI Antibody Titers for 4 FLU Vaccine Strains Expressed as MGI
RatioCo-Ad GroupControl Group
Flu A/Darwin/6/2021 H3N2 HI5.10 (4.60 to 5.66)6.87 (6.12 to 7.71)
Flu A/Victoria/2570/2019 H1N1 HI3.85 (3.40 to 4.35)3.79 (3.34 to 4.31)
Flu B/Austria/1359417/2021 Victoria HI1.89 (1.77 to 2.03)1.84 (1.71 to 1.98)
Flu B/Phuket/3073/2013 Yamagata HI1.94 (1.82 to 2.07)2.11 (1.97 to 2.27)
SecondaryPercentage of Participants Reporting Each Solicited Administration Site Event After Each Vaccine Dose Administration

The solicited administration site events after vaccination include erythema, pain and swelling.

Time frame:
Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for CoAd Group and at Day 1 and Day 31 for Control group)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Each Solicited Administration Site Event After Each Vaccine Dose Administration
Percentage of participantsCo-Ad GroupControl Group
Erythema, FLU dose given at Day 16.6 (4.6 to 9.1)5.3 (3.5 to 7.6)
Erythema, RSV dose given at Day 114.1 (11.3 to 17.5)—
Erythema, RSV dose given at Day 31—12.4 (9.5 to 15.8)
Pain, FLU dose given at Day 151.7 (47.3 to 56.1)44.8 (40.5 to 49.3)
Pain, RSV dose given at Day 166.1 (61.8 to 70.2)—
Pain, RSV dose given at Day 31—58.8 (54.1 to 63.3)
Swelling, FLU dose given at Day 15.2 (3.5 to 7.5)6.0 (4.1 to 8.5)
Swelling, RSV dose given at Day 110.5 (8.0 to 13.4)—
Swelling, RSV dose given at Day 31—8.4 (6.0 to 11.4)
SecondaryPercentage of Participants Reporting Each Solicited Systemic Event After Each Dose Administration

The solicited systemic events after vaccination include fever, headache, fatigue, myalgia and arthralgia.

Time frame:
Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 and Day 31 for C-oAd Group and at Day 1 and Day 31 for Control group)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Each Solicited Systemic Event After Each Dose Administration
Percentage of participantsCo-Ad GroupControl Group
Arthralgia, Dosing at Day 125.8 (22.1 to 29.8)15.6 (12.6 to 19.0)
Arthralgia, Dosing at Day 31—17.1 (13.7 to 20.9)
Fatigue, Dosing at Day 145.7 (41.4 to 50.1)28.5 (24.6 to 32.6)
Fatigue, Dosing at Day 31—30.4 (26.2 to 34.9)
Fever, Dosing at Day 12.1 (1.1 to 3.8)0.6 (0.1 to 1.7)
Fever, Dosing at Day 31—1.1 (0.4 to 2.6)
Headache, Dosing at Day 132.2 (28.2 to 36.4)19.3 (16.0 to 23.0)
Headache, Dosing at Day 31—23.9 (20.1 to 28.2)
Myalgia, Dosing at Day 139.0 (34.7 to 43.3)23.0 (19.4 to 26.9)
Myalgia, Dosing at Day 31—31.9 (27.6 to 36.5)
SecondaryPercentage of Participants Reporting Unsolicited Adverse Events (AEs)

An unsolicited AEs is an AE that is not included in a list of solicited events using a Participant Electronic Diary. Unsolicited events must be spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).

Time frame:
Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine administration
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Unsolicited Adverse Events (AEs)
Percentage of participantsCo-Ad GroupControl Group
Percentage of Participants Reporting Unsolicited Adverse Events (AEs)13.6 (10.8 to 16.8)24.5 (20.9 to 28.4)
SecondaryPercentage of Participants Reporting at Least One Serious Adverse Event (SAEs)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant.

Time frame:
From Day 1 until 6 months after last vaccination (Month 6 for the Co-Ad Group, Month 7 for the Control group)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least One Serious Adverse Event (SAEs)
Percentage of participantsCo-Ad GroupControl Group
Percentage of Participants Reporting at Least One Serious Adverse Event (SAEs)4.0 (2.5 to 6.1)6.9 (4.9 to 9.4)
SecondaryPercentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMDs)

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e., pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.

Time frame:
From Day 1 until 6 months after last vaccination (Month 6 for the Co-Ad Group, Month 7 for the Control group)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMDs)
Percentage of participantsCo-Ad GroupControl Group
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMDs)0 (0 to 0.7)0.6 (0.1 to 1.7)

Adverse events

Collected over Solicited AEs were collected during 7-day follow-up period after each vaccination. Unsolicited AEs were ollected during 30-day follow-up period after each vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to study end [6 months after last vaccination]).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Co-Ad Group0/523 (0%)21/523 (4%)427/523 (81.6%)
Control Group6/522 (1.1%)36/522 (6.9%)428/522 (82%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventCo-Ad GroupControl Group
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/5233/522
OsteoarthritisMusculoskeletal and connective tissue disorders0/5233/522
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders0/5232/522
BronchitisInfections and infestations2/5230/522
COVID-19Infections and infestations2/5230/522
Atrial fibrillationCardiac disorders2/5231/522
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations1/5231/522
Respiratory syncytial virus infectionInfections and infestations1/5231/522
Respiratory tract infectionInfections and infestations1/5231/522
Complicated appendicitisInfections and infestations0/5231/522
Most frequent other events
Showing 10 of 113
Most frequent other events
EventCo-Ad GroupControl Group
Injection site painGeneral disorders368/523349/522
FatigueGeneral disorders236/523212/522
MyalgiaMusculoskeletal and connective tissue disorders201/523206/522
HeadacheNervous system disorders167/523164/522
ArthralgiaMusculoskeletal and connective tissue disorders133/523133/522
Injection site erythemaGeneral disorders83/52376/522
Injection site swellingGeneral disorders67/52361/522
NasopharyngitisInfections and infestations13/52315/522
COVID-19Infections and infestations11/52314/522
PyrexiaGeneral disorders14/5239/522

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Co-Ad GroupControl GroupTotal
Mean72.1 ± 5.472.2 ± 5.272.2 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Co-Ad GroupControl GroupTotal
Female255275530
Male268247515
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Co-Ad GroupControl GroupTotal
American Indian or Alaska Native123
Asian011
Black or African American011
White5225161038
Multiple011
Other - Unspecified011
08

Study locations

37 sites
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Erpent, 5101, Belgium
  • GSK Investigational Site
    Genk, 3600, Belgium
  • GSK Investigational Site
    Ieper, 8900, Belgium
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Clermont-Ferrand Cedex 1, 63003, France
  • GSK Investigational Site
    Limoges Cedex, 87042, France
  • GSK Investigational Site
    Lyon cedex 04, 69317, France
  • GSK Investigational Site
    Montpellier cedex 5, 34295, France
  • GSK Investigational Site
    Nîmes cedex 9, 30029, France
  • GSK Investigational Site
    Paris, 75679, France
  • GSK Investigational Site
    Pierre-Bénite, 69495, France
  • GSK Investigational Site
    Marbella - Málaga, Andalucia 29603, Spain
  • GSK Investigational Site
    Benalmádena, Málaga, 29630, Spain
  • GSK Investigational Site
    Boadilla Del Monte (Madrid), 28660, Spain
  • GSK Investigational Site
    Burgos, 09006, Spain
  • GSK Investigational Site
    Centelles, 08540, Spain
  • GSK Investigational Site
    La Roca Del Valles (Barcelona), 08430, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain
  • GSK Investigational Site
    Santander (Cantabria), 39008, Spain
  • GSK Investigational Site
    Valladolid, 47005, Spain
  • GSK Investigational Site
    Vic, 28500, Spain
  • GSK Investigational Site
    Soham, Cambridgeshire CB7 5JD, United Kingdom
  • GSK Investigational Site
    Bollington, Cheshire SK10 5JH, United Kingdom
  • GSK Investigational Site
    Chippenham, Wiltshire SN15 2SB, United Kingdom
  • GSK Investigational Site
    Blackpool, FY3 7EN, United Kingdom
  • GSK Investigational Site
    Bristol, BS37 4AX, United Kingdom
  • GSK Investigational Site
    Chippenham, SN14 6GT, United Kingdom
  • GSK Investigational Site
    Peterborough, PE8 6PL, United Kingdom
09

References and documents

Publications

  • Clark R, Davies S, Labrador J, Loubet P, Natalini Martinez S, Morinigo HM, Nicolas JF, Vera MP, Ramet M, Rebollo-Rodrigo MH, Sanz-Munoz I, Dezutter N, Germain S, David MP, Jayadev A, Amare Hailemariam H, Kotb S, Meyer N. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. Clin Infect Dis. 2024 Oct 15;79(4):1088-1098. doi: 10.1093/cid/ciae365. PubMed 39099085 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Feb 2023, 4 months.

Results were first posted in Mar 2024, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 6, 2022
StartActual
Oct 14, 2022
Primary completionActual
Feb 17, 2023
CompletionActual
Jul 17, 2023
Results first posted
Mar 15, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05568797
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Oct 14, 2022
Primary completion
Feb 17, 2023
Completion
Jul 17, 2023
Results posted
Mar 15, 2024
Last update
Sep 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion